$AMRN - On our trading list. Disaster court ruling on Monday, but at least 2 analysts still see value here. We think there is still going to be Vascepa sales and this company will still be making money. At just $4 a share, the reaction to the down side from the court case maybe a buy-able overreaction.Amarin surprise loss of Vascepa case 'not game over,' says Cantor Fitzgerald Cantor Fitzgerald analyst Louise Chen said Amarin's loss of its Vascepa patent case was surprising, but she expects the stock to "over-correct" and then potentially bounce back from there as she contends that it is "not game over yet." After catching up with Amarin's management, she noted that the company will appeal the ruling and said that the decision does not affect international opportunities in the EU, China and rest of the world, which "could still total billions of dollars in sales." Chen keeps an Overweight rating and $35 price target on Amarin shares.Amarin shares could recover over time, says JPMorgan Given the unknowns, including how close Vascepa generics are to securing approvals and whether the generics would launch at-risk prior to an appellate ruling, it is possible that Amarin shares could recover over time as these variables are clarified, JPMorgan analyst Jessica Fye tells investors in a research note. In the near-term, however, the analyst sees the possibility of an at-risk launch representing an overhang on the stock. Fye keeps a Neutral rating on Amarin shares. $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page